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Abstract 
An important function of transcription factors may be to sequester coactivators or corepressors of transcription. In this manner transcription factors 
could regulate in trans the activity of promoters to which they do not bind. This may be of widespread significance as a mechanism to control cell 
cycle-dependent and differentiation-specific transcriptional activity within eukaryotic cells. Therefore squelching in vivo may be more important than 
hitherto appreciated. 
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Eukaryotic gene regulation can be viewed as an inter- 
play between opposing activating and repressing influ- 
ences. Transactivation of genes is controlled at many 
levels, but typically involves binding by transcription 
factors to specific regulatory sites within the promoter. 
Transactivation domains (TADS) within many transcrip- 
tion factors mediate interactions with other components 
affecting transcriptional initiation [ 1,2]. These TADS en- 
able a factor not only to transactivate but also to squelch 
at higher concentrations. Squelching is repression of 
transcription by sequestering limiting components (e.g. 
coactivators) required for transcriptional activation 
away from the promoter in the affected gene [1,3]. Simi- 
lar processes could also enhance transcription by seques- 
tering repressors of transcription (Fig. 1). 
Mechanistically, squelching of RNA polymerase II- 
driven transcription could operate at different levels. 
TADS could interfere with general components of the Pol 
II holoenzyme [4] such as TFIIB [5], or TFIID [6]. Inter- 
actions with TFIID could be at the level of the TATA- 
binding protein (TBP), or TBP associated factors (TAFs) 
[7-91. Since different types of TFIID may exist, with both 
common and unique TAFs [9, lo], squelching via a given 
TAF could potentially affect all TFIID-mediated tran- 
scription, or only a subset of promoters requiring that 
TAF. Thus squelching offers the potential for transcrip- 
tional repression at either a panoramic level, or restricted 
to subsets of genes whose promoters rely on the availa- 
bility of specific factors not universally required. For 
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instance the p53 protein can repress TATA box-medi- 
ated, but not initiator element-mediated transcription, 
by interacting with basal transcription factors [ll], 
whereas acidic TADS squelch activated but not basal 
transcription [3]. Alternatively, the targets of squelching 
could be non-TAF coactivators which could affect inter- 
actions between histones or transcription factors and the 
promoter, or stabilize an active initiation complex by 
bridging between the nascent TATA-complex and DNA- 
bound transactivators [3,12-161. The oncoprotein Bcl-3 
provides an example of a non-TAF coactivator of NF- 
rcB p50B homodimer-driven transcription [ 171. 
We would like to draw attention to a potential level of 
regulation which has received scant consideration: 
namely that squelching may be a common mechanism 
employed by transcription factors to down-regulate pro- 
moters whose activity is governed by coactivators of low 
abundance. It is interesting to note that viruses often 
attack the cell at the level of coactivator imitation or 
exploitation, altering the transcriptional environment to 
one more conducive to their own growth [18-201. That 
the cell is susceptible to this type of exploitation suggests 
that coactivator availability should indeed be crucial in 
determining the transcriptional profile of the cell. In the 
following discussion we document just a few cases which 
suggest that squelching may be a regulatory mechanism 
within eukaryotic cells. 
The estrogen hormone receptor was shown to inhibit 
the transcriptional activation mediated by the progester- 
one and glucocorticoid receptors. This inhibition was 
independent of the DNA-binding and dimerization do- 
main of the estrogen receptor and could be attributed to 
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Fig. 1. Corepressors may compete with coactivators to influence tran- 
scription. Schematized representation of a DNA-bound transcription 
factor interacting with a corepressor (R) or coactivator (A). A corepres- 
sor could block transactivation, or recruit one or more additional coac- 
tivating factors (X) to transactivate. Such a hypothetical group of 
coactivators acting in series has been referred to as a ‘coactivator 
cascade’ [12]. An excess of TADS can squelch activated transcription. 
Although depicted as interacting directly with the TAD, a corepressor 
could conceivably bind elsewhere to sterically prevent coactivator re- 
cruitment, or to allosterically affect the affinity of the TAD for the 
coactivator. While represented as affecting only activated transcription, 
squelching could also affect basal levels by sequestration of components 
of RNA Pol II holoenzyme (e.g. [l 11). 
both the N-terminal A/B and the C-terminal hormone 
binding domains, which both contain a TAD. Recipro- 
cally, transactivation mediated by the estrogen receptor 
was inhibited by the progesterone or glucocorticoid re- 
ceptors [21]. This inhibition, independent of the DNA- 
binding function, strongly suggests a competition for 
coactivators. These studies were dependent on the over- 
expression of steroid hormone receptors and might 
therefore be artifactual. However, it was shown in two 
breast cancer cell lines expressing solely endogenous ster- 
oid hormone receptors that estrogen-dependent tran- 
scription could also be blocked by the addition of agonis- 
tic ligands of the progesterone and glucocorticoid recep- 
tors. Furthermore, the antiprogesterone/antiglucocorti- 
coid ligand RU486 alleviated this repression [21]. This 
indicates that, upon activation by interaction with ag- 
onistic ligands, a TAD localized in the hormone binding- 
domain may sequester coactivators required by other 
steroid receptors, and presumably additional factors. 
The transcription factor AP-1 consists of members of 
the proto-oncoprotein families Jun and Fos [22]. Mutual 
antagonism between AP-1 and various steroid receptor 
transcription factors has been often observed [22-241 and 
in some instances is probably due to squelching. This was 
shown for cJun and c-Fos, which trans-repress estrogen 
receptor-activated transcription in transient transfection 
experiments. This is independent of the b-ZIP DNA- 
binding domain of cJun, but probably requires the 
TADS and therefore may involve squelching [25]. A 
coactivator activity from F9 embryonal carcinoma (EC) 
stem cells, necessary for transactivation by v-Jun, cJun 
and JunB, has been identified as a target of squelching 
by v-Jun and c-Jun [26]. 
Additionally to interference with steroid receptors, the 
AP-1 members c-Jun, JunB and c-Fos can effectively 
repress transactivation by the muscle specific proteins 
myogenin and MyoD in transfection experiments. How- 
ever this is not so for JunD, which is constitutively ex- 
pressed in muscle cells [27]. The majority of mutual re- 
pression between MyoD and c-Jun seems to occur via a 
direct interaction involving the leucine zipper of cJun 
and the helix-loophelix motif of MyoD [28]. However 
deleting the c-Jun leucine zipper did not completely alle- 
viate repression, and c-Fos also mediated repression yet 
did not interact with MyoD, implying that squelching 
could be involved. Similarly, McBride et al. [29] observed 
that exogenous c-Fos, c-Jun, Fra-1, FosB and v-Fos 
could all trans-repress the region of the ANF promoter 
which confers cardiac muscle specificity. This repression 
did not require an AP-1 binding site in the promoter, a 
b-ZIP domain in cJun or the C-terminus of c-Fos in- 
volved in repression of the c-fos promoter (see below). 
However the repressing molecules all possessed a func- 
tional TAD, suggesting that the TADS of c-Fos and 
c-Jun titrated away a non-abundant muscle-specific 
coactivator. Thus transcription factors with Fos- or Jun- 
like TADS can potentially trans-repress tissue specific 
expression independently of their DNA-binding or 
dimerization functions in transfection experiments, im- 
plying that squelching may regulate differentiation-spe- 
cific transcription. 
In quail fibroblasts, the transcription factor Myb can 
activate the HSP70 promoter independently of a Myb 
DNA-binding site in the promoter, or of the Myb DNA- 
binding domain upon transient transfection [30]. This 
could be due to the sequestering of a repressor. Myb can 
also activate a promoter containing a Myb binding site 
in the same cells. Activation requires the DNA-binding 
domain of Myb and, indicative of squelching, can be 
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suppressed by Myb overexpression independently of a 
DNA-binding domain in the suppressing molecule [31]. 
Further evidence suggesting the existence of squelching 
as a regulatory mechanism is provided by the existence 
of the B-Myc molecule. It is homologous to the N-termi- 
nal TAD of c-Myc but lacks a basic region and helix- 
loophelix motif, and suppresses transactivation by c- 
Myc [32]. Such a protein, homologous only to a TAD, 
may function to inhibit transcriptional activation by 
other proteins with similar TADS. B-Myc may thus rep- 
resent a ‘regulatory squelching’ factor. 
Another case may involve the transcription factor NF- 
KB. The p50 and ~65 subunits heterodimerise to activate 
promoters containing NF-KB binding sites. A naturally 
occurring splice variant of p65 has been identified (p65d) 
which is unable to dimerize or bind DNA, but contains 
a functional TAD, and whose mRNA is abundant in 
non-differentiated hematopoietic cells [33]. Transfection 
of p65d transformed fibroblasts and interfered with NF- 
KB-induced transcription upon T-cell activation, but 
only when the TAD was functional, leading to specula- 
tion that p65d somehow permits unrestricted prolifera- 
tion [33]. While this work included non-transfected pri- 
mary cells the mechanism of action of p65d remains 
unclear. The TAD is clearly important, so a squelching- 
type mechanism seems plausible. 
The serum response element (SRE) is a promoter ele- 
ment which confers not only rapid induction but also 
repression to a variety of immediate early genes. It is 
bound by several proteins including the serum response 
factor (SRF) [34]. Introduction of an SRE in front of a 
reporter gene activates the reporter in non-induced 
NIH3T3 cells. This indicates that SRE-bound SRF me- 
diates activation. However, even very low doses of 
cotransfected exogenous SRF expression plasmid lead to 
an SRE-dependent repression of transcription [35-371. 
Therefore endogenous SRF may already be in the 
squelching region of its dose-response curve. Thus any 
up-regulation of the endogenous SRF gene might con- 
comitantly lead to repression of promoters relying on 
SRF for activity, via squelching. Such an up-regulation 
occurs for instance after the induction of quiescent cells 
[38] and may contribute to the postinductional down- 
regulation of immediate early genes. Therefore this mode 
of squelching could be an important regulator of the 
transient transcription of immediate early genes in the 
transition from the G,, to Gi phases of the cell cycle. 
Interestingly, it has been found that SRF activates 
transcription in reconstituted in vitro transcription reac- 
tions, but additionally exerts squelching at higher con- 
centrations, possibly via a coactivator which is utilized 
not only by SRF but also by other factors such as VP16 
[39]. If the Fos protein could also interact with this coac- 
tivator, it could explain how c-Fos represses the c-fos and 
several other immediate early gene promoters via SREs 
[34,40], namely by sequestering a coactivator required 
for SRF-dependent transcription. This type of repression 
is apparently independent of the DNA-binding function 
of c-Fos but requires the C-terminus of the protein [40- 
43] and therefore may involve squelching. 
The retinoblastoma protein (Rb) and the related mol- 
ecule ~107 are examples of corepressors. They interact 
with E2F and can be recruited to promoters in a complex 
with E2F, thereby preventing E2F-mediated transactiva- 
tion [44]. Not only do viral transforming proteins such 
as the adenovirus ElA protein imitate coactivator activ- 
ities by binding to TFIID [20], they also activate E2F 
sites by binding to Rb and ~107 [44], thereby depriving 
the cell of corepressors. Thus they attack the cell at pre- 
cisely the levels at which we propose squelching may be 
able to regulate transcription. 
Perspective 
The observation that squelching can suppress muscle 
differentiation-specific transcription in cultured cells (see 
above) implies that this type of regulation is possible 
endogenously and may be widely relevant. For example, 
a potential strategy to differentiate cell lineages during 
development would be to express combinations of differ- 
ent but related molecules, whose absolute concentra- 
tions, and ratios relative to each other, could influence 
the availability of different transcriptional coactivators 
in separately differentiating cells. The Hox genes in- 
volved in embryo pattern formation [45] are ideal candi- 
dates for this type of regulation. We emphasize in this 
model that regulation of promoters bound by Hox pro- 
teins may not be the sole means by which members of the 
Hox gene family specify the differentiation status of a cell 
or tissue. The non-homologous regions of the proteins 
may selectively sequester a variety of coactivators, thus 
pleiotropically affecting the transcriptional activity of a 
broad range of genes in trans. 
In conclusion, squelching could be a commonly occur- 
ring transcriptional regulatory mechanism. The poten- 
tial for regulatory squelching by transcription factors is 
accompanied by a number of corollaries. (i) Sequestering 
of coactivators could in some cases be the most impor- 
tant function of a particular transcription factor. (ii) Any 
promoter whose activity is dependent on the availability 
of a coactivator could be influenced by the expression of 
a broad range of unrelated transcription factors. (iii) A 
transcription factor with several TADS could trans- 
repress some promoters via squelching with one TAD, 
while activating other promoters in cis using a different 
TAD. (iv) DNA-binding-independent transcriptional 
controls should be considered indispensable when assess- 
ing the phenotype imposed by a transcription factor. (v) 
Finally, this concept has serious ramifications for inter- 
preting tissue culture and transgenic animal studies in- 
volving constitutive overexpression of transcription fac- 
tors. 
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